KR20190046894A - 항생제 화합물 - Google Patents

항생제 화합물 Download PDF

Info

Publication number
KR20190046894A
KR20190046894A KR1020197008269A KR20197008269A KR20190046894A KR 20190046894 A KR20190046894 A KR 20190046894A KR 1020197008269 A KR1020197008269 A KR 1020197008269A KR 20197008269 A KR20197008269 A KR 20197008269A KR 20190046894 A KR20190046894 A KR 20190046894A
Authority
KR
South Korea
Prior art keywords
benzo
oxazole
alkyl
trifluoromethyl
oxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197008269A
Other languages
English (en)
Korean (ko)
Inventor
닥터 폴 메오
닥터. 나와즈 칸
Original Assignee
디스쿠바 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디스쿠바 엘티디. filed Critical 디스쿠바 엘티디.
Publication of KR20190046894A publication Critical patent/KR20190046894A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197008269A 2016-08-22 2017-08-22 항생제 화합물 Withdrawn KR20190046894A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1614314.1A GB201614314D0 (en) 2016-08-22 2016-08-22 Antibiotic compounds
GB1614314.1 2016-08-22
PCT/GB2017/052478 WO2018037223A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds

Publications (1)

Publication Number Publication Date
KR20190046894A true KR20190046894A (ko) 2019-05-07

Family

ID=57045563

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008269A Withdrawn KR20190046894A (ko) 2016-08-22 2017-08-22 항생제 화합물

Country Status (15)

Country Link
US (1) US20190194179A1 (https=)
EP (1) EP3500567A1 (https=)
JP (1) JP2019528291A (https=)
KR (1) KR20190046894A (https=)
CN (1) CN109923111A (https=)
AU (1) AU2017316742A1 (https=)
BR (1) BR112019003427A2 (https=)
CA (1) CA3034000A1 (https=)
CO (1) CO2019002624A2 (https=)
EA (1) EA201990551A1 (https=)
GB (1) GB201614314D0 (https=)
MX (1) MX2019001978A (https=)
PH (1) PH12019500360A1 (https=)
SG (1) SG11201901374WA (https=)
WO (1) WO2018037223A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230106356A (ko) * 2022-01-06 2023-07-13 충남대학교산학협력단 신규한 화합물 및 이를 포함하는 결핵균 또는 비결핵항산균 감염질환 치료용 약제학적 조성물

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7503051B2 (ja) 2018-10-11 2024-06-19 バイエル・アクチエンゲゼルシヤフト イミダゾール誘導体の製造方法
EP3636645A1 (de) 2018-10-11 2020-04-15 Bayer Aktiengesellschaft Verfahren zur herstellung schwefel-substituierter pyridinderivate
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
US20220125763A1 (en) 2019-02-22 2022-04-28 Anifera Limited Compositions providing enhanced antibacterial activity against gram-positive bacteria and use thereof
CN111808093B (zh) * 2019-04-12 2023-05-16 中国医学科学院医药生物技术研究所 一种新德里金属-β-内酰胺酶-1抑制剂
WO2020210339A1 (en) 2019-04-12 2020-10-15 Mitobridge, Inc. Hmox1 inducers
US12528798B2 (en) 2019-10-29 2026-01-20 Lg Chem, Ltd. Compound for crop protectant
WO2022108354A1 (ko) * 2020-11-19 2022-05-27 주식회사 에이엔제이사이언스 신규 화합물, 이의 제조방법 및 이를 포함하는 항생제 조성물
CN113185475A (zh) * 2021-04-29 2021-07-30 江苏永凯化学有限公司 一种高效低污染的精恶唑禾草灵生产工艺
CN117043141A (zh) * 2021-05-31 2023-11-10 江苏亚虹医药科技股份有限公司 7-硝基-8-羟基喹啉衍生物、其制备方法及其医药用途
WO2023234970A1 (en) * 2022-06-01 2023-12-07 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of hif-1/2a pathway inhibition, and induction of ferroptosis
WO2024130173A1 (en) * 2022-12-16 2024-06-20 Immvention Therapeutix Benzimidazole derivatives
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CN117003710A (zh) * 2023-07-19 2023-11-07 镇江先锋植保科技有限公司 一种2-巯基-6-氯苯并恶唑的制备方法
CN121889378A (zh) * 2023-09-01 2026-04-17 英孚欣治疗生物技术公司 取代的苯并噁唑基氨基苯并噁唑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604217B2 (en) * 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP5786402B2 (ja) * 2011-03-29 2015-09-30 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
WO2016039939A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230106356A (ko) * 2022-01-06 2023-07-13 충남대학교산학협력단 신규한 화합물 및 이를 포함하는 결핵균 또는 비결핵항산균 감염질환 치료용 약제학적 조성물

Also Published As

Publication number Publication date
WO2018037223A1 (en) 2018-03-01
CA3034000A1 (en) 2018-03-01
EP3500567A1 (en) 2019-06-26
SG11201901374WA (en) 2019-03-28
AU2017316742A1 (en) 2019-04-11
CO2019002624A2 (es) 2019-05-31
JP2019528291A (ja) 2019-10-10
US20190194179A1 (en) 2019-06-27
MX2019001978A (es) 2019-08-01
BR112019003427A2 (pt) 2019-05-21
GB201614314D0 (en) 2016-10-05
PH12019500360A1 (en) 2019-11-11
CN109923111A (zh) 2019-06-21
EA201990551A1 (ru) 2019-12-30

Similar Documents

Publication Publication Date Title
KR20190046894A (ko) 항생제 화합물
US11795164B2 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
KR100882377B1 (ko) 치환된 이속사졸 및 항생제로서의 이들의 용도
CN111566099B (zh) 抗菌化合物
JP2020536082A (ja) 細菌感染症を治療するためのクロマンモノバクタム化合物
JP2009529008A (ja) N−ホルミルヒドロキシルアミン化合物
BG99791A (en) 5-member heteroaryloxazolidinons
KR20110093925A (ko) 항세균성 화합물
ES2268011T3 (es) Oxazolidinonas que contienen un grupo sulfonimida como antibioticos.
JP6150841B2 (ja) クロストリジウム・ディフィシル関連疾患を治療するための化合物
JP2010531868A (ja) 3−スピロピリミジントリオン−キノリン誘導体と抗菌剤としてのその使用
KR20090042971A (ko) 항미생물 활성을 갖는 신규한 마크로라이드 및 케토라이드
TW201815390A (zh) 包含抗生素化合物及雜環化合物之組合物及其於預防或治療細菌感染之用途
US6281210B1 (en) Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent
EP3638664A1 (en) Benzofuran amides and heteroaromatic analogues thereof for use in therapy
CA2405532A1 (en) Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
CN101616588B (zh) 取代的哌啶子基苯基噁唑烷酮
JP5662940B2 (ja) 新規な抗微生物薬
US20170007615A1 (en) Antibacterial Compounds
KR100872059B1 (ko) 아미독심 또는 하이드록사마이드 기를 가지는 신규한옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
KR100777149B1 (ko) 데할로게노 화합물
WO2017189866A1 (en) Polymyxin analogs useful as antibiotic potentiators
CN107108646A (zh) 阿根诺卡菌素类化合物及其作为抗菌剂的用途
JP2009525318A (ja) 抗菌剤としてのベンズイソオキサゾールオキサゾリジノン
WO2014195697A1 (en) Novel pyrrole derivative

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190321

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200701

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20201007

WITB Written withdrawal of application